Groundbreaking Prostate Cancer Imaging Initiative
Prostate cancer stands as the most frequently diagnosed non-skin cancer among men in the United States, and it ranks fourth globally in terms of diagnosis rates. Sarasota Memorial Research Institute is excited to share its involvement in the Solar-Stage study, sponsored by Curium, which aims to improve the characterization of this disease. This clinical trial will explore the efficacy of a new investigational diagnostic agent, Copper Cu 64 PSMA I&T Injection, known for its potential to create detailed images of prostate tumors through advanced imaging techniques such as positron emission tomography (PET) and computed tomography (CT) scans.
Importance of Accurate Staging
Understanding the Study
The primary goal of this clinical trial is to ascertain whether Copper Cu 64 PSMA I&T Injection can safely and effectively facilitate accurate prostate cancer staging. Accurate imaging is crucial as it informs treatment strategies and can greatly influence patient outcomes. It is essential to note that the safety and effectiveness of Copper Cu 64 PSMA I&T have not yet been validated by the United States Food and Drug Administration.
Comprehensive Evaluation Process
Participants involved in the study will go through a thorough evaluation process. They will attend an initial screening session to review their medical history and provide consent. Following this, an imaging session will take place where the Copper Cu 64 PSMA I&T Injection will be administered alongside PET/CT scans to gather precise images of the prostate cancer tumors. Regular follow-up care will be provided to monitor any potential side effects and ensure patient well-being. Additionally, if surgical intervention is necessary, intraoperative findings may also contribute invaluable data to this research.
Expert Insights on Prostate Cancer Treatment
Expert Commentary
Dr. Robert I. Carey, MD PhD FACS, who is leading the research study, emphasizes the significance of surgical interventions for prostate cancer. He states, "Higher risk of prostate cancer at diagnosis correlates with the enhanced benefits that come from robotic prostatectomy paired with extended pelvic lymph node dissection. I am hopeful that the findings from the Curium 64 Solar Stage Research Study will better delineate the extent of disease prior to surgical approaches, possibly allowing us to target and manage lymph nodes that are otherwise neglected in standard treatments. This innovation could mean a lot for patients, enabling them to avoid future aggressive therapies. We feel privileged to offer such a study to our patients."
Eligibility Criteria for Participants
Inclusion Criteria
Those interested in participating in the study must meet the following criteria:
- Male individuals aged 18 years and older, with confirmed prostate adenocarcinoma.
- Scheduled for a prostatectomy involving pelvic lymph node dissection.
- Identified as having unfavorable intermediate-risk, high-risk, or very high-risk prostate cancer based on the NCCN Guidelines Version 1.2023.
- Able to understand and sign a written informed consent document.
Exclusion Criteria
In contrast, individuals will be excluded from study participation under these conditions:
- Previous treatments such as androgen deprivation therapy, chemotherapy, radiation, or local ablation before the scheduled prostatectomy.
- Being part of another interventional clinical trial in the past 30 days, or having received an investigational product within five biological half-lives prior to study drug administration.
- Any medical issue that may affect study integrity, including the incapacity to undergo PET scans.
- Recent use of x-ray contrast or another PET radiotracer before the PET scan.
- Known hypersensitivity to the investigational product's components.
- A PSMA PET scan conducted as part of standard care within 90 days before enrollment.
Advancing Medical Research
Sarasota Memorial Research Institute remains devoted to cultivating medical research and enhancing patient care through pioneering clinical trials. The Curium 64 Solar Stage Research Study is a substantial step forward, potentially offering new diagnostic avenues that could reshape prostate cancer therapeutic approaches.
Contact Information
To learn more about the trial and eligibility requirements, interested individuals are encouraged to contact Sarasota Memorial's Research Institute at (941) 917-2225. The institute is dedicated to delivering advanced treatments for patients across the Suncoast community, underscoring its commitment to innovative research. For additional information on clinical studies or chances to participate in clinical trials, reach out to the Sarasota Memorial Research Institute or contact Dr. Carey’s office directly at (941)-917-5400.
Frequently Asked Questions
What is the purpose of the Solar-Stage study?
The Solar-Stage study aims to evaluate the efficacy and safety of the Copper Cu 64 PSMA I&T Injection for imaging prostate cancer tumors.
Who can participate in the study?
Male patients aged 18 or older with confirmed prostate adenocarcinoma and scheduled for prostatectomy with specific risk classifications are eligible.
How does the imaging process work?
Participants will receive the Copper Cu 64 PSMA I&T Injection followed by PET/CT scans to capture detailed images of cancerous tumors.
What are the potential benefits of the study?
This study could help improve the accuracy of prostate cancer staging, guiding treatment options and potentially improving patient outcomes.
How can I get more information about the trial?
For more information, interested individuals can contact the Sarasota Memorial Research Institute at (941) 917-2225 for further details.
